This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1
[Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and
tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.
Phase:
Phase 2
Details
Lead Sponsor:
Verrica Pharmaceuticals Inc.
Collaborators:
BioClinica, Inc. Instat Consulting, Inc. Paidion Research, Inc.